HCPCS Code J1453: Injection, Fosaprepitant, 1 mg

## **J1453 documentation requirements** The documentation requirements for this fosaprepitant injection generally include: - Documentation should include the indication for use, such as prevention of chemotherapy-induced nausea and vomiting (CINV) and symptom reduction. - Infusion should be completed about 30 minutes prior to chemotherapy. - Medical records must support the administration, including status, dosage, mg amount, and timing. - Documentation may require information on patient response, including reduction in nausea and vomiting and absence of unacceptable toxicity. - Billing documentation should specify the amount administered, as one billable unit equals 1 mg. - Providers may need to document relevant patient clinical information, such as body surface area or other criteria if applicable, depending on payer policies. - Written ordering and administration documentation are generally required to be maintained for up to seven years from the date of service in compliance with Medicare and other insurers. - Specific instructions on documentation fields for claims (e.g., Remarks/Additional Claim Information fields) may be needed per certain payer guidelines.

## **J1453 billing requirements** The billing requirements for HCPCS Code J1453 (Injection, fosaprepitant, 1 mg) include the following key points: - A cancer diagnosis code must be reported with the claim; without a cancer diagnosis, claims will be denied. This aligns with its use primarily for chemotherapy-induced nausea and vomiting prevention. - The drug must be billed in multiples of the dosage specified (1 mg per unit). If the exact dose is not a multiple of 1 mg, the dosage should be rounded up to the next whole unit. - Payment for J1453 is typically based on the average sales price (ASP) or the submitted charge, whichever is lower, according to Medicare Part B drug pricing policies. - For outpatient hospital settings, payment is made under the Ambulatory Payment Classification (APC) system, and specific billing instructions apply when the drug is dispensed as part of oral antiemetic regimens. - Infusion should be completed about 30 minutes prior to chemotherapy administration, with the usual single dose being 150 mg (150 units), which is reflected in maximum billing units allowed. - Providers should maintain detailed medical documentation supporting the administration, dosage, timing, and indication to justify the claim. - Claims for subsequent doses of oral antiemetics related to this drug may be billed separately under different guidelines. - Providers are responsible for following payer-specific guidelines, including modifier use, claim form requirements, and supporting clinical documentation. These requirements align with Medicare claims processing manuals and drug pricing files, emphasizing proper diagnosis coding, dosage rounding, and ASP-based payment rates to ensure compliant billing for J1453.

## **Other relevant codes** Other relevant HCPCS codes related to J1453 (Injection, fosaprepitant, 1 mg), used for the prevention of chemotherapy-induced nausea and vomiting (CINV), include: - **J0185**: Injection, aprepitant, 1 mg — another NK1 receptor antagonist antiemetic. - **J1434**: Injection, fosaprepitant (Focinvez), 1 mg — a branded formulation similar to J1453 but distinct. - **J1454**: Injection, fosnetupitant 235 mg and palonosetron 0.25 mg — a combination antiemetic for CINV. Additionally, other relevant codes for assessment related to chemotherapy-induced nausea and vomiting include: - **G9021 to G9025 series**: Chemotherapy assessment codes for nausea, vomiting, and other symptoms, patient-reported during chemotherapy administration, used especially in certain Medicare projects. For oral antiemetics connected to this treatment area: - **Q0162**: Ondansetron 1 mg, oral, an antiemetic used as a substitute for IV antiemetics.